The Role of Inflammation in Cardiovascular Disease.
Henein MY, Vancheri S, Longo G, Vancheri F. · 2022
Read The Role of Inflammation in Cardiovascular Disease. by Henein MY, Vancheri S, Longo G, Vancheri F. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9658900.txt.
Introduction
Henein and co-authors examine the role of inflammation in cardiovascular disease. Atherosclerosis is now read as a chronic inflammatory disease. Inflammation harms the vessel lining and lets lipoproteins slip inside. White blood cells gather at the site and platelets switch on.
Monocytes that enter the wall turn into macrophages. Their flavor, pro- or anti-inflammatory, steers plaque fate. A lipid rich dead core grows under a collagen cap over time. In chronic inflammation, macrophages eat into that cap. The thin capped plaque can then burst without warning. Stress, ageing, and clonal blood changes feed the fire as well. Cytokines such as IL-1 and IL-6 carry the signal chain. Trials of drugs that block those paths cut heart attacks and strokes. The trade off is a higher risk of infections, they note.
Catalog record
| CREATOR | Henein MY, Vancheri S, Longo G, Vancheri F. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The Role of Inflammation in Cardiovascular Disease By Michael Y. Henein, Sergio Vancheri, Giovanni Longo, Federico Vancheri, Maria Addolorata Bonifacio, Maria Addolorata Mariggiò Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms232112906 ABSTRACT Atherosclerosis is a chronic inflammatory disease, in which the immune system has a prominent role in its development and progression. Inflammation-induced endothelial dysfunction results in an increased permeability to lipoproteins and their subendothelial accumulation, leukocyte recruitment, and platelets activation. Recruited monocytes differentiate into macrophages which develop pro- or anti-inflammatory properties according to their microenvironment. Atheroma progression or healing is determined by the balance between these functional phenotypes. Macrophages and smooth muscle cells secrete inflammatory cytokines including interleukins IL-1β, IL-12, and IL-6. Within the arterial wall, low-density lipoprotein cholesterol undergoes an oxidation. Additionally, triglyceride-rich lipoproteins and remnant lipoproteins exert pro-inflammatory effects. Macrophages catabolize the oxidized lipoproteins and coalesce into a lipid-rich necrotic core, encapsulated by a collagen fibrous cap, leading to the formation of fibro-atheroma. In the conditions of chronic inflammation, macrophages exert a catabolic effect on the fibrous cap, resulting in a thin-cap fibro-atheroma which makes the plaque vulnerable. However, their morphology may change over time, shifting from high-risk lesions to more stable calcified plaques. In addition to conventional cardiovascular risk factors, an exposure to acute and chronic psychological stress may increase the risk of cardiovascular disease through inflammation mediated by an increased sympathetic output which results in the release of inflammatory cytokines. Inflammation is also the link between ageing and cardiovascular disease through increased clones of leukocytes in peripheral blood. Anti-inflammatory interventions specifically blocking the cytokine pathways reduce the risk of myocardial infarction and stroke, although they increase the risk of infections. 1. INTRODUCTION Over the last two decades, clinical and experimental studies have shown that atherosclerosis is a low-grade, sterile, inflammatory disease [1,2]. Systemic and local inflammation have a central role in the development and progression of cardiovascular disease (CVD), from endothelial dysfunction to clinical syndromes [3,4,5,6]. Inflammatory biomarkers have been shown to predict CVD, independently of traditional risk factors [7,8,9]. Several acute and chronic conditions, including the traditional risk factors, psychological stress, autoimmune disease, microbial and viral infections, and ageing, can activate endothelial damage and dysfunction (Table 1) [10,11,12,13,14,15,16,17,18,19,20,21,22,23,24]. In turn, this promotes a vascular low-grade inflammatory response, leading to the progression of atherosclerosis [25]. Hence, inflammation is a common mechanism linking traditional and emerging CV risk factors to the development of atherosclerosis, leading to CAD, large artery thrombotic stroke, and cerebral aneurysms [1,26,27,28,29]. All phases of atherosclerosis, from retention of atherogenic lipoproteins within the arterial wall, to plaque development and rupture, involve a complex network, including innate and adaptive immune systems, bone marrow, and spleen, which modulate the pro-inflammatory and anti-inflammatory activities of protein mediators, such as cytokines, and immune cells such as leukocytes, macrophages, and lymphocytes [30]. The role of inflammation in the atherosclerosis is confirmed by the effects of statins in reducing the CV risk. Several studies have shown that most beneficial effects of statins are due to the reduction in vascular inflammation, to some extent, independent of their lipid-lowering action [31,32,33]. Moreover, nearly one-half of patients undergoing high-intensity lipid-lowering treatment with statins in a secondary prevention trial have a residual inflammatory risk and an increased risk of major CV events, despite significant lipid-lowering effects [34,35,36,37,38]. In the last few years, the inflammatory biology of atherosclerosis has been translated into therapeutic strategies. Recent clinical trials indicated that targeting inflammation results in a lower incidence of CAD and stroke [39,40,41]. This review summarizes the current knowledge about the role of inflammation and the immune system in the development of atherosclerosis, the progression to stable and vulnerable plaque, the relationship between the central nervous system and arterial inflammatory response, the role of ageing in promoting atherosclerosis beyond a prolonged exposure to the traditional risk factors, and new therapeutic opportunities targeting inflammation to reduce the CVD burden. Although most studies refer to CAD, the relationship between inflammation and atherosclerosis in coronary and cerebral arteries is based on the same mechanisms [1,27,42]. Endothelial dysfunction. The vascular endothelium has a critical role in transducing the risk factors into CVD. In normal individuals, the endothelium has anti-inflammatory and antithrombotic properties, and regulates the permeability to circulating molecules and the vascular tone through the balance between the release of vasodilator substances, such as nitric oxide (NO), and endothelium-derived constrictors, such as endothelin [43]. The CV risk factors, as well as bacterial and viral infections, and environmental stress, reduce the bioavailability of NO, resulting in the loss of these protective properties, the damage of endothelial junctions, and an increase in the permeability to macromolecules. These changes lead to a subendothelial accumulation of cholesterol-containing lipoproteins which triggers a low-grade inflammatory response (Figure 1) [44,45]. Several studies have shown a strong relationship between low-density lipoprotein cholesterol (LDL-C) and atherosclerosis [46,47]. Once in the subendothelial space, LDL-C undergo an oxidation and aggregation in large complexes. Moreover, in an inflammatory environment, the lipoprotein metabolism is shifted from large- and medium-size LDL-C towards small and dense (sdLDL-C) sub-fractions with a lower affinity to the liver specific LDL-C receptor [48]. Elevated levels of sdLDL-C are associated with the increased risk of CAD [49,50]. These particles have a greater atherogenicity than larger ones because of the reduced clearance from the liver LDL receptors, resulting in a greater persistence in the blood. Hence, they are more likely to enter the arterial wall due to their small size. These properties increase the exposure of the arterial wall to sdLDL-C and favour their atherogenic intravascular modification, such as oxidation, thus making them pro-inflammatory and activating the overlying endothelium. Despite large evidence of the causal relationship between oxidized LDL-C and atherosclerosis, many CV events which occur in individuals with LDL-C levels are currently considered to be normal, even in the absence of the conventional risk factors [51,52]. Moreover, in recent years, the large increase in the prevalence of type 2 diabetes and obesity, and the control of LDL-C with effective treatment, shifted the lipid risk profile in the population from elevated LDL-C to elevated triglyceride-rich lipoproteins (TRL) and remnant lipoproteins (RLP), which are more strongly associated with inflammation than LDL-C [50,53,54,55,56,57]. Modified lipoproteins in the subendothelial space are taken by macrophages and also by dendritic cells, which are mononuclear phagocytes “resident” in the normal arterial wall since fetal life, independently of atherosclerosis [58,59,60,61]. Activated endothelial cells and macrophages produce cytokines and adhesion molecules, such as the vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, and E-selectin, on the endothelial surface of the artery. Circulating monocytes originating from the bone marrow or the spleen, adhere to the endothelial layer, migrate into the intima by diapedesis, and differentiate into macrophages [2,62,63]. Additionally, endothelial cells can undergo an endothelial-mesenchymal transition (EMT) and migrate into the intima, thus contributing to intimal thickening and inflammation [64,65]. These changes are the first step in the development of atherosclerosis, preceding angiographic or ultrasound evidence [30,45,66,67]. The endothelial inflammatory response includes the coordinate activation of both innate immunity (macrophages) and adaptive immunity (T- and B-lymphocytes, dendritic cells) [44,68]. Leukocytes involvement in inflammation and atherosclerosis has also been shown by human positron emission tomography (PET) studies, using 18F-fluorodeoxyglucose (18F-FDG), a glucose analogue extensively used as a marker of